We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+29.85%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$3.09B
AUM Growth
+$304M
Cap. Flow
-$377M
Cap. Flow %
-12.21%
Top 10 Hldgs %
47.14%
Holding
153
New
43
Increased
25
Reduced
27
Closed
29

Top Buys

Rank Stock Value
1
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
+$99.9M
2
ABBV icon
AbbVie
ABBV
+$92.7M
3
LRMR icon
Larimar Therapeutics
LRMR
+$41.5M
4
WBA
Walgreens Boots Alliance
WBA
+$40.8M
5
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$36.4M

Top Sells

Rank Stock Value
1
AUXL
AUXILIUM PHARAMCEUTICALS INC
AUXL
+$216M
2
AGN
Allergan Inc
AGN
+$129M
3
RNA
PROSENSA HLDGS N V ORD SHS (NLD)
RNA
+$62.2M
4
NVRO
NEVRO CORP.
NVRO
+$40.5M
5
AERI
Aerie Pharmaceuticals
AERI
+$36.3M

Sector Composition

Rank Sector Weight
1 Healthcare 60.38%
2 Financials 2.52%
3 Technology 0.47%
4 Industrials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACHN
26
DELISTED
Achillion Pharmaceuticals
ACHN
$27.7M 0.9%
2,810,164
-110,136
-4% -$1.38M
CRL icon
27
Charles River Laboratories
CRL
$10.6B
$22.9M 0.74%
+289,450
New +$21.4M
OFIX icon
28
Orthofix Medical
OFIX
$469M
$22.6M 0.73%
630,222
+96,410
+18% +$3.03M
ALIM
29
DELISTED
Alimera Sciences
ALIM
$22.1M 0.72%
294,705
+24,983
+9% +$1.97M
PTLA
30
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$21.8M 0.71%
574,546
-81,013
-12% -$2.78M
MCK icon
31
McKesson
MCK
$98B
$20.8M 0.67%
92,000
– –
LOXO
32
DELISTED
Loxo Oncology, Inc
LOXO
$19.8M 0.64%
1,591,546
– –
GILD icon
33
PUT
Gilead Sciences
GILD
$166B
$19.6M 0.64%
200,000
– –
INGN icon
34
Inogen
INGN
$171M
$19.3M 0.62%
601,772
+247,442
+70% +$7.99M
AERI
35
DELISTED
Aerie Pharmaceuticals
AERI
$19M 0.62%
606,118
-1,252,799
-67% -$36.3M
DYAX
36
DELISTED
DYAX CORPORATION
DYAX
$19M 0.61%
1,131,414
+148,669
+15% +$2.31M
HUM icon
37
Humana
HUM
$47.6B
$18.9M 0.61%
+106,300
New +$16.8M
PACB icon
38
Pacific Biosciences
PACB
$419M
$17.8M 0.58%
3,048,310
-2,072,461
-40% -$14.3M
TRUP icon
39
Trupanion
TRUP
$1.15B
$16.8M 0.54%
2,101,848
-576,328
-22% -$4.38M
NUVA
40
DELISTED
NuVasive, Inc.
NUVA
$15.6M 0.5%
+338,194
New +$15.7M
ELV icon
41
Elevance Health
ELV
$83.6B
$15.4M 0.5%
+99,742
New +$14.2M
NSTG
42
DELISTED
NanoString Technologies, Inc.
NSTG
$14.9M 0.48%
1,460,652
+537,274
+58% +$6.59M
TARA icon
43
Protara Therapeutics
TARA
$230M
$14.7M 0.48%
31,634
– –
IMPR
44
DELISTED
IMPRIVATA, INC COM
IMPR
$14.4M 0.47%
1,025,652
+27,400
+3% +$378K
TPST icon
45
Tempest Therapeutics
TPST
$15.4M
$14.1M 0.46%
139
-75
-35% -$9.99M
AAC
46
DELISTED
AAC Holdings
AAC
$13.6M 0.44%
+446,328
New +$13.1M
AXGN icon
47
Axogen
AXGN
$2.1B
$13.5M 0.44%
3,870,824
+2,363,000
+157% +$8.12M
TXMD icon
48
TherapeuticsMD
TXMD
$24M
$13.5M 0.44%
+44,466
New +$10.9M
JUNO
49
DELISTED
Juno Therapeutics, Inc.
JUNO
$11.1M 0.36%
183,149
-175,000
-49% -$8.49M
STDY
50
DELISTED
SteadyMed Ltd
STDY
$10.8M 0.35%
+1,267,733
New +$10.9M
1
2
3 4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q1 2015 Portfolio in Review

As of Q1 2015, Deerfield Management held 153 positions worth $3.09B, up 11% from $2.78B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Deerfield Management withdrew a net $377M in Q1 2015, closing 29 positions and reducing 27 holdings. Its most notable exit was AUXILIUM PHARAMCEUTICALS INC, an estimated $216M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 60% of assets, up from 52% a quarter earlier, followed by Financials and Technology.

Against the trend, Deerfield Management opened a new position in AbbVie worth $89.8M.

  • Deerfield Management's largest Q1 2015 buy was AbbVie: 1,534,000 shares worth $89.8M.
  • Deerfield Management added most to AUSPEX PHARMACEUTICALS INC COM STK (DE) in Q1 2015, an estimated $99.9M increase.
  • Deerfield Management's biggest Q1 2015 reduction was Aerie Pharmaceuticals, cutting an estimated $36.3M.
  • Deerfield Management fully exited AUXILIUM PHARAMCEUTICALS INC in Q1 2015, selling an estimated $216M.
  • Deerfield Management's ten largest holdings make up 47% of its $3.09B portfolio in Q1 2015.
  • Deerfield Management opened 43 new positions and closed 29 in Q1 2015.
  • Deerfield Management's portfolio value rose 11% quarter-over-quarter to $3.09B.

Based on Deerfield Management's 13F filing for Q1 2015, filed 15 May 2015.